Abstract：
The investigation of the real-world use of the extemporaneous combination of nebivolol and amlodipine (NA-EXC) in adult patients diagnosed with hypertension in Europe.
Retrospective analysis of data extracted from seven databases of patient medical records and prescriptions from Italy, Germany, France, Hungary, and Poland, to determine the prevalence and incidence of NA-EXC use and to estimate the number of patients potentially eligible for a single-pill combination of the two antihypertensives. Secondary objectives included: the description of the population of NA-EXC users and the assessment of their adherence to treatment based on the proportion of days covered.
The use of NA-EXC was found to be common in Europe and ranged between 2.9% to 9.9% of all patients identified in the databases with a prescription of nebivolol and/or amlodipine. The estimated numbers of patients potentially eligible in 2019 for a single-pill combination of nebivolol and amlodipine in Italy and Germany were, respectively, 178,133 and 113,240. Users of NA-EXC were mostly aged 70-79 years, had metabolic disorders and other comorbidities; >70% of them had received ≥2 concomitant medications before starting NA-EXC. Adherence to NA-EXC was defined as high only in 15.6% to 35% of patients.
The extemporaneous combination of nebivolol and amlodipine is commonly prescribed in Europe, however adherence to the therapy is poor. The development of a single-pill combination of nebivolol and amlodipine may improve adherence by reducing the number of pills administered to patients and thus simplifying treatment regimens.
Retrospective analysis of data extracted from seven databases of patient medical records and prescriptions from Italy, Germany, France, Hungary, and Poland, to determine the prevalence and incidence of NA-EXC use and to estimate the number of patients potentially eligible for a single-pill combination of the two antihypertensives. Secondary objectives included: the description of the population of NA-EXC users and the assessment of their adherence to treatment based on the proportion of days covered.
The use of NA-EXC was found to be common in Europe and ranged between 2.9% to 9.9% of all patients identified in the databases with a prescription of nebivolol and/or amlodipine. The estimated numbers of patients potentially eligible in 2019 for a single-pill combination of nebivolol and amlodipine in Italy and Germany were, respectively, 178,133 and 113,240. Users of NA-EXC were mostly aged 70-79 years, had metabolic disorders and other comorbidities; >70% of them had received ≥2 concomitant medications before starting NA-EXC. Adherence to NA-EXC was defined as high only in 15.6% to 35% of patients.
The extemporaneous combination of nebivolol and amlodipine is commonly prescribed in Europe, however adherence to the therapy is poor. The development of a single-pill combination of nebivolol and amlodipine may improve adherence by reducing the number of pills administered to patients and thus simplifying treatment regimens.
摘要：
目的：在欧洲诊断为高血压的成年患者中，对奈比洛尔和氨氯地平（NA-EXC）的临时组合使用的真实世界进行调查。方法：回顾性分析从七个意大利患者病历和处方数据库中提取的数据，德国,法国,匈牙利,波兰,确定NA-EXC使用的患病率和发生率，并估计可能符合两种抗高血压药的单药组合的患者人数。次要目标包括：对NA-EXC使用者人群的描述以及根据所覆盖天数的比例评估他们对治疗的依从性。结果：发现NA-EXC的使用在欧洲很普遍，在数据库中确定的所有患者中，奈比洛尔和/或氨氯地平的处方占2.9％至9.9％。在意大利和德国，2019年可能有资格使用奈比洛尔和氨氯地平单药组合的患者人数估计为，分别,178133和113240。NA-EXC的用户大多年龄在70-79岁之间，有代谢紊乱和其他合并症;>70%的患者在开始NA-EXC之前接受了≥2种合并用药.对NA-EXC的依从性仅在15.6%至35%的患者中被定义为高。结论：奈比洛尔和氨氯地平的临时组合在欧洲是常见的，然而，对治疗的依从性较差。奈必洛尔和氨氯地平的单药丸组合的开发可以通过减少向患者施用的药丸的数量并因此简化治疗方案来改善依从性。
